NCT01544504撤回1 期
Exploratory Study of Topical Norepinephrine in Post-Surgical Breast Cancer Patients Receiving Radiotherapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Safety of daily topical application of norepinephrine to the radiation field
研究概览
简要总结
This study, a nonrandomized open-label safety and exploratory study, will evaluate the safety of topical norepinephrine in post-surgical breast cancer patients who are undergoing radiation therapy.
The study will also provide information about whether topical norepinephrine can prevent or decrease the severity of the radiation dermatitis experienced by these patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Subjects must:
- •be ≥ age 18 years of age with a documented pathological diagnosis of Stage Ia (T1, N0, M0), Stage Ib (T0 or 1, N1mic, M0), Stage IIA (T0-T1N1M0, T2N0M0) or Stage IIB (T2N1M0, T3N0M0) infiltrating ductal or lobular carcinoma of the breast or ductal carcinoma in situ (DCIS).
- •be post-surgical patients scheduled to be treated with at least 50 Gy to the whole breast and axilla using standard radiation techniques (an additional 10-16 Gy boost to the lumpectomy region may also be delivered). All radiation treatment is to be delivered based on standard CT planning.
- •be at higher than average risk for radiodermatitis, as evidenced by a separation at the posterior tangent field border of ≥ 24 cm or a bra cup size of C or greater [breast size criterion].
- •have the ability to understand the informed consent document.
- •be able to comply with protocol schedule.
- •have a negative serum pregnancy test (within 7 days prior to starting radiation therapy), if a female of child bearing potential.
- •consent to utilize medically acceptable methods of contraception throughout the study period if of child-bearing potential.
排除标准
- •with unhealed surgical wounds or scars in the study treatment area.
- •with underlying active untreated cardiac disease (e.g. arrhythmia).
- •with generalized skin disorders that have required treatment within the past 6 months.
- •with connective tissue disorders.
- •with rashes, ulcerations, or poorly healed scars in the study drug application area.
- •with a known allergy to norepinephrine.
- •with a known clinically significant abnormal ECG within the past 6 months. If the Principal Investigator feels that the ECG findings are of clinical significance, the patient will excluded or sent for a cardiac consult (insignificant abnormalities such as sinus tachycardia and sinus bradycardia may be allowed at the discretion of the Principal Investigator).
- •receiving MAO inhibitors or antidepressants (triptyline or imipramine types).
- •who are pregnant or breastfeeding.
- •with lymphovascular space invasion on pathology.
- •with dermal lymphatic invasion on pathology.
- •with close proximity of the tumor to the overlying skin within the SDAS (as evidenced by a depth of less than 5 mm on ultrasound or MRI [if performed] and a linear distance of less than 2 cm from the SDAS), or a diagnosis of inflammatory breast cancer.
- •receiving concurrent neoadjuvant or adjuvant chemotherapy for their breast cancer.
- •with previous radiation to the breast to be treated.
- •taking β-blockers.
- •with NCI CTC Version 4.0 grade 2 or higher hypertension at the time of study entry.
研究组 & 干预措施
Norepinephrine
Experimental
Topical norepinephrine
干预措施: Norepinephrine (Drug)
结局指标
主要结局
Safety of daily topical application of norepinephrine to the radiation field
时间窗: Safety will be assessed for up to 11 weeks following the start of treatment.
The primary safety hypothesis is that there will be little or no skin irritation associated with the application of the topical norepinephrine and no systemic effects secondary to transdermal absorption.
次要结局
- Efficacy of daily topical application of norepinephrine to the radiation field(Efficacy will be assessed for up to 11 weeks following the start of treatment..)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
4 期
How Maxvida High-Protein Formula Affects Adults Needing Tube Feeding with the Same CaloriesCTRI/2024/06/068511Signtura Health and nutrition
进行中（未招募）
1 期
An open-label clinical study to evaluate the safety and antiepileptic activity of ganaxolaone in treatment of patients diagnosed with infantile spansms.EUCTR2006-004286-33-PLMarinus Pharmceuticals, Inc.54
进行中（未招募）
不适用
An open-label clinical study to evaluate the safety and antiepileptic activity of ganaxolaone in treatment of patients diagnosed with infantile spasms.EUCTR2006-004286-33-CZMarinus Pharmceuticals, Inc.54
进行中（未招募）
1 期
Clinical study to find out whether methylene blue injection is safe and effective in the treatment of a blood disorder (methemoglobinemia) resulting from exposure to toxic agents (drugs or environmental poisons)Acquired methemoglobinemiaMedDRA version: 20.0Level: LLTClassification code 10054290Term: Acquired methemoglobinemiaSystem Organ Class: 100000004851EUCTR2017-000290-37-GBProvepharm SAS10
进行中（未招募）
1 期
Clinical study to find out whether methylene blue injection is safe and effective in the treatment of a blood disorder (methemoglobinemia) resulting from exposure to toxic agents (drugs or environmental poisons)Acquired methemoglobinemiaMedDRA version: 20.0Level: LLTClassification code 10054290Term: Acquired methemoglobinemiaSystem Organ Class: 100000012871EUCTR2017-000290-37-FRProvepharm SAS10